1P-AL-LAD

1P-AL-LAD
Clinical data
Routes of
administration		Oral
Identifiers
IUPAC name
  • (6aR,9R)-N,N-diethyl-4-propanoyl-7-prop-2-enyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide
CAS Number
PubChem CID
Chemical and physical data
FormulaC25H31N3O2
Molar mass405.542 g·mol−1
3D model (JSmol)
SMILES
  • CCC(=O)N1C=C2C[C@@H]3C(=C[C@H](CN3CC=C)C(=O)N(CC)CC)C4=C2C1=CC=C4
InChI
  • InChI=1S/C25H31N3O2/c1-5-12-27-15-18(25(30)26(7-3)8-4)13-20-19-10-9-11-21-24(19)17(14-22(20)27)16-28(21)23(29)6-2/h5,9-11,13,16,18,22H,1,6-8,12,14-15H2,2-4H3/t18-,22-/m1/s1
  • Key:GAGOTJNMWJYWMB-XMSQKQJNSA-N

1P-AL-LAD is a derivative of lysergic acid diethylamide (LSD) which has psychedelic effects and has been sold as a designer drug. It is believed to act as a prodrug for AL-LAD and produces a head-twitch response in animal studies.[1]

Interactions

See also

References

  1. ↑ Brandt SD, Kavanagh PV, Westphal F, Pulver B, Schwelm HM, Whitelock K, Stratford A, Auwärter V, Halberstadt AL (August 2022). "Analytical profile, in vitro metabolism and behavioral properties of the lysergamide 1P-AL-LAD". Drug Testing and Analysis. 14 (8): 1503–1518. doi:10.1002/dta.3281. PMC 9546273. PMID 35524430.
This article is issued from WikiProjectMed. The text is available under Creative Commons Attribution-ShareAlike License unless otherwise noted. Additional terms may apply for the media files.